Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stop losses taken out. The mm is out of shares. This will run today if played right. Set high stop losses for low float runner out of stock
Thanks CC. TTF, you and me been here long enough to know the real story of TMHO!
Your welcome
buddy! I hate it when I can't complete the picture. Now it's all coming together! This was part of Tmho's original business all along. Great days ahead
His add on tradeboss.com for investors into his power generation projects:
http://www.tradeboss.com/default.cgi/action/viewcompanies/companyid/582570/
Do you remember the early guys on the TMHO board mentioning Richard Reuth snd his involvement with TMHO? Well here is a message that was posted back in March 24 2010:
tvmetguy
Share
Wednesday, March 24, 2010 9:50:06 AM
Re: None Post # of 2201
The 120 mil in assests is key, it is an estimate by them, but this is combining, Aquagreen, a 100 plot "green" home development of which they have 7 homes built, and the assets of the 2 main players Richard Reuth and Dave Ghashghai. Richard is the owner of Champion Landscape Supplies in Houston and also CEO of H2O Power, which holds a 45% stake in 7200 acres of timber and gold mining land in Guyana! David is the inventor of a program that tracks doctors around the world, allowing travelers to seek medical attention abroad. This is how you get 120 mil.
The 1 bil in rev is what they hope, but they have to raise cash first to get all idea off of the ground. They said they will not be diluting stock as they wish to gain investors money buy issuing direct debt!
IMO, take 120 mil in assets, and say they will need 60 mil in debt to get all things running, you are looking at a 60 mil company here with an OS of 164 mil, or PPS of .36. Holy chit batman.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=48187394
H20 Power Technology Inc. is the company that TMHO announced a LOI for the Cuyuni Concessions in Cuyana. Pr'ed on 3/14/2011
http://www.otcmarkets.com/stock/TMHO/news
I remember all of this but was fuzzy on the details
Thank you!
Mother Load it indeed it could be! I wonder the percentage TMHO stake is in the Guyana concessions?
Here is some of the product links for the one subsidiary, Chefs Selections:
http://www.amazon.com/Chefs-Selection-Seasoning-Gift-Package/dp/B00132C818
Chef Selections has two business units:
1. Chefs Selections Gourmet Foods
2. Passion 4 Life Liquid Vitamins and Minerals
Jerry Rapplean has been the Chief Operating Officer of Passion 4 Life Liquid Vitamins & Minerals of Chef Selections Inc., since May 2008. Mr. Rapplean is a highly regarded and respected Marketing Professional. Mr. Rapplean has held senior positions at several of the most successful network marketing-based companies over the past 25 years, including The Shaklee Corporation, Rexall Showcase International, and YH International. He served as the Director of Worldwide Sales ...
Passion4life and CFSC PR link
http://www.marketwire.com/press-release/Passion-4-Life-Liquid-Vitamins-Minerals-Supplement-Offers-Health-Conscience-Consumers-876450.htm
Passion4Life product link:
http://www.passion4lifevitamins.com/ingredients.html
Passion4Life/CFSC is a JV/marketing partnership and concluded in May 2008 by CFSC. Last year the co. name was changed from Chef Selections to Talisman Holdings, Inc through acquisition of the AOP Worldwide. Ticker changed from CFSC to TMHO.
To date there is 2 gold mines one in Peru and now Guyana.
NON COMPLIANT MEANS:
K1. Why does my business entity’s status show Noncompliant? I am still in business and continue to pay my taxes.
If an entity fails to file its Periodic Report or fails to maintain a registered agent, the entity’s status will become “Noncompliant”.
Entities are given 3 months to file the Periodic Report. If the report is not received by the due date, or if a new registered agent is not appointed within 30 days after the resignation of the current registered agent, the entity will become “Noncompliant”.
If the entity’s status is “Noncompliant”, a Periodic Report must be filed, or, if the entity has failed to maintain a registered agent, a Statement of Change Changing the Registered Agent Information must be filed to return the entity’s status to “Good Standing”. To file a Periodic Report or a Statement of Change, go to the Business Home page, click “File a document affecting an existing record”, search for your entity, confirm you found the correct entity, and then select the document to be filed.
NON COMPLIANT DOESN"T MEAN IT"S A FRAUDULANT COMPANY. ALSO WHAT PROOF DO YOU HAVE OF THE SS CHANGED TO 1Bill+?
BAHOO TMHO failed to file a report or registered agent change. One that is easily remedied! I've been a LONG in TMHO for 1year and know this company inside and out. Today is the first time you are posting on this board and it's non factual BS bashing. Your previous post didn't even have the right website link so I will supply it:
http://www.talismanholdings.com/
We could be in for quite a ride come Monday and weeks to come. THIS IS HUGE GOLD. I should add if TMHO can fund these concessions. Logical way is similar to what GoldFields Inc did. The company etablished a new subsidiary, Guyana GoldFields Inc. Took it public and got underwriting from major investment firms. Guyana GoldFields Inc (GUY.TO) is trading at $9.71 close of Friday.
The Aranka Gold Mining property (owned by Guyana GoldFields a subsidiary of GoldFields is next to the TMHO concessions.
See the map in this report on page: 8.
http://ws6287982413.websoon.com/docs/Micon_Report.pdf
MUST READ:
A lot of new eyes here today. I did DD around known mining projects in the North West Cuyuni area and found this very interesting and promising presentation on ACQUISITION OF GOLD MINING CONCESSIONS
UPPER and LOWER IROMA and SHARARIN
by KYNASTON & ASSOCIATES LTD.
NC. INYO MINING GUYANA, INC./JUPITER FINANCIAL GROUP, I
and
JOINT VENTURE COMPANY
http://www.jfg.us.com/images/KAL-Inyo_Concessions_Powerpoint_-_July_2008.pdf
Just another source to confirm that it at least appears there is significant gold veins running from east to west in the region and the AUG/T is very high. Need a N43-101 geological survey report to confirm this. I expect the next PR to be about JV/financing for this project.
BINGO: and here is the link to the actual Guyuni Mining Project and concession that TMHO is referring to in the PR of 4/7:
http://cuyunigold.com/summary-of-project/guyana-mining-project
I owe TMHO stock for about 1year now before the R/M. Long Term play here..
A lot of new eyes here today. I did DD around known mining projects in the North West Cuyuni area and found this very interesting and promising presentation on ACQUISITION OF GOLD MINING CONCESSIONS
UPPER and LOWER IROMA and SHARARIN
by KYNASTON & ASSOCIATES LTD.
NC. INYO MINING GUYANA, INC./JUPITER FINANCIAL GROUP, I
and
JOINT VENTURE COMPANY
http://www.jfg.us.com/images/KAL-Inyo_Concessions_Powerpoint_-_July_2008.pdf
Just another source to confirm that it at least appears there is significant gold veins running from east to west in the region and the AUG/T is very high. Need a N43-101 geological survey report to confirm this. I expect the next PR to be about JV/financing for this project.
I owe TMHO stock for about 1year now before the R/M. Long Term play here.....
How could 10Mill shares have gone into the market when the total shares traded since 3/14 is only +/- 6.5Mil shares? I agree there was one seller that sold a boat load of shares yesterday and perhaps over the last 3 days. History trading volume on this stock has always been below 200K since the R/M last year.
Yes I do and CBBD can do a forward split UPTO 200:1 split and that will get us onto a senior exchange. Most peeps sees a stock split as a negative. If it's executed right and there is a SOLID management team with a good Business strategy in place then it's immaterial in the big picture. I'm looking at the BIG picture here (next12-24months) and somebody on the IHUB board wrote today that CBBD is different from the other CHINA growth stocks on the OTC/Pinksheets because we have a US CEO/President and other US directors on the board with the best track records in this industry. And that is what I am going with + the tremendous opportunity and non competition for VOD in the Chinese market.
Hope that happens. I need more time to clear funds and would love to buy up these 2's next week again.
WOW He got himself in Ihub Jail..Good for him! <lol>
I've been in RAMO since the beginning of January and holding since 01. Increased my position numerous times in the low to mid 2's. This is a GREAT buying opportunity.
With 1X LOI and 2X MOU's in the works and to be announced soon this will bounce again several more times to higher highs and eventually reach the target PPS of 0.20 if not more. Look at some of the other stocks the HDOGTX is in, and been holding for quite sometime. He doesn't post on those boards, all day everyday. QSGIQ is the only one I've seen him posting almost daily.
Just as a side note, I've noticed that he was pretty quite this week and not posting as much as he normally does. He can be on vacation or under the weather this week.
Just my 2cents. Too many people going to the dark side to soon on these boards. HDDOGTX is one of the good ones on IHUB.
Oliveira Capital LLC that Mr Oliveira sole owner and was the investing firm that CBBD was using. Owes 9.94% of stock.
It looks like they are reorganizing their financing. Maybe a bigger investment firm to obtain more financing for future growth? That will make sense since CBBD management is gearing up to move us to a senior exchange.
Also there was a large block of shares purchased yesterday afternoon (1.6Mill) so something BIG coming?
Buys outnumbered sells 2 to 1 today. Nice
I own 1.235MMil shares and looking to pick up anything I can down here. This is at least a 12month hold. Did you take a look at the CBBD powerpoint presentation that was presented last month to the NEw York Investor community? Good starting point and shows the full anticipated growth plan 2011-2015
I put CBBD in the same class of growth potential as BIDU (5years ago) and GAME (2years ago)
Yip. That is what I am hoping for. This company is going to be unbelievable in 2011
Nice close to HOD. Should see a green north movement rest of the week.
This could get real interesting if we get a good 10K or a PR AH/premarket
Maybe MM's doing some short covering. CBBD have significant failure to deliver.
Short Selling Data
Short Interest 72,770 (18,801.301%)
Mar 15, 2011
Significant Failures to Deliver Yes - Reg SHO
Hoping for fins. Something is up. In the last hour almost 1.5Mil in shares traded.
Sudden volume surge.Is the 10K out yet?
Hubei Holley Zhengyuan Pharmaceutical Co., Ltd. operates as a pharmaceutical distributor. The company is based in Wuhan, China. Hubei Holley Zhengyuan Pharmaceutical Co., Ltd. operates as a subsidiary of Beijing Holley Jiuzhou Pharmaceutical Co. Ltd. As per the transaction announced on December 10, 2008, Hubei Holley Zhengyuan Pharmaceutical Co., Ltd. operates as a subsidiary of Wuhan Jianmin Pharmaceutical Group Co. Ltd.
No.7032 Dong Xihu Ave.
Dong Xihu Dist.
Wuhan, 430040
China
Sorry...Just to clarify Hubei Holley Zhenyuan Pharmaceutical Company Limited does business with Zhenyuan Pharmaceutical Co. ; Ltd. Zhenyuan Pharmaceutical Co. ; Ltd is NOT the acquired company.
I'm putting a DD piece together on the Hubei Holley Zhenyuan Pharmaceutical Company Limited and will posted that when it's ready
8K filing excerpt filed by BFAR on 3/9/2011 to address matter of their previous CPA not licensed, refilings of 2009-10K and 2009 10Q's and appointing new auditors to do re-audits of 2009 filings and auditing of 2010 filings:
On January 24, 2011, we filed a Current Report on Form 8-K (the “Report”) reporting that we had terminated Etania Audit PC (formerly known as Davis Accounting Group PC), our registered independent public accountant (the “Former Accountant’). This amendment is being filed to provide additional information relating to the Former Accountant and to file as an exhibit to the Report the letter from the Former Accountant stating whether he agrees with the statements in the Report.
Item 4.01. Changes in Registrant's Certifying Accountant.
Termination of Principal Accountant
We have been advised that the licenses of Edwin Reese Davis, Jr. and his firm, the Davis Accounting Group, P.C, lapsed on September 30, 2008 and were formally revoked as of November 4, 2010 by the Utah Division of Occupational & Professional Licensing (the “DOPL”). We also understand that the successor firm, Etania Audit Group P.C. is not licensed to practice by the Utah DOPL.
We had engaged the Former Accountant, which continues to appear on the list of Registered Independent Public Accountants registered with the Public Accounting Oversight Board, to audit the financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2009 (the “2009 Form 10-K”), and the Former Accountant issued a report on those financial statements which was included in the 2009 Form 10-K, despite the fact that it was not then licensed to practice.
We have received a letter of comment from the Securities and Exchange Commission concerning the 2009 Form 10-K and the audit report of the Former Accountant included therein in respect of our financial statements for the years ended December 31, 2008 and 2009, stating that we may not include the audit report of the Former Accountant in our 2009 because the Former Accountant was not licensed as of the date of the audit report and, accordingly, our financial statements for the years ended December 31, 2008 and 2009 are not considered to be audited. Accordingly, we will file an amendment to our 2009 Form 10-K deleting the audit report of the Former Accountant included in our 2009 Form 10-K and indicating that the financial statements as at December 31, 2008 and 2009 and the years th en ended have not been audited.
As previously reported in our Current Report on Form 8-K filed on February 14, 2011, we have engaged Acquavella, Chiarelli, Shuster, Berkower & Co. LLP (the “New Accountant”) to audit our financial statements to be included in our Annual Report on Form 10-K for the year ended December 31, 2010 (the “2010 Form 10-K”), which will include our financial statements as at December 31, 2009 and 2010 and the years then ended, and the audit report of the New Accountant thereon. Following the filing of the 2010 Form 10-K and after the inclusion therein of the audit report of the New Accountant on our financial statements as at and for the year ended December 31, 2009, we will file a further amendment to our 2009 Form 10-K to include the audi t report of the New Accountant on our financial statements as at and for the year ended December 31, 2009.
Link to the filing:
http://secwatch.com/bfar/8k/a/events-or-changes-between-quar/2011/3/9/7629914
Shenzhen Zhijun Pharmaceutical Co.,Ltd 1company with 137.2Mil USD (RMB900Mill) assets, annual sales 182.93Mil USD (RMB1,200Mill). See profile below and from company website @http://szzhijun.com/english/about.aspx?id=25
Formerly named Shenzhen Pharmaceutical Factory, Shenzhen Zhijun Pharmaceutical. Co.ltd was established in 1985, playing a key role in SINOPHARM cephalosporin manufacturing lineup and also representing the core manufacturing enterprise in Shenzhen Accord Pharm.
With over 20 years’ endeavor, Zhijun has developed into a national High-Tech Enterprise focusing on Quality, Efficiency and Technology, with total assets equal to RMB900 million, annual turnover reach RMB1,200 million, and annual interest duty over RMB 100million. Now Zhijun has grown to a National Hi-Tech Enterprise among the list of Top 50 Pharmaceutical Factory in China.
Zhijun is strong in manufacturing Respiratory and Anti-infective pharmaceutical products, owns an international standardized R&D premise of 45,000 square kilometers, 9 production lines within 5 workshops which are powder for injection, oral solution and oral solid ( for cephalosporins and non-cephalosporins ). The company is in line with the EU GMP quality management, produced a series of market leading products with stringent quality control and management system and powerful marketing network. DaliXin (Cefuroxime axetil tablets and capsules) is the best player, leading the Dali brand and Zhijun brand to the top of the marketplace. The company is expanding the business in overseas markets and building strong reputation profile in global marketplace.
The Zhijun Product line has extended to the healthcare and OTC products. In the near future, Zhijun Pharma will take advantage of the SINOPHARM manufacture and sales integration, combine the API supplying to reduce the production cost and expand the scale, thus driving itself to be the core enterprise in the China Pharmaceutical Group Manufacturing lineup.
NICE COMPANY.....Shareholders of the company
Shenzhen Zhijun Pharmaceutical Co.,Ltd. Profile:
Formerly named Shenzhen Pharmaceutical Factory, Shenzhen Zhijun Pharmaceutical. Co.ltd was established in 1985, playing a key role in SINOPHARM cephalosporin manufacturing lineup and also representing the core manufacturing enterprise in Shenzhen Accord Pharm.
With over 20 years’ endeavor, Zhijun has developed into a national High-Tech Enterprise focusing on Quality, Efficiency and Technology, with total assets equal to RMB900 million, annual turnover reach RMB1,200 million, and annual interest duty over RMB 100million. Now Zhijun has grown to a National Hi-Tech Enterprise among the list of Top 50 Pharmaceutical Factory in China.
Zhijun is strong in manufacturing Respiratory and Anti-infective pharmaceutical products, owns an international standardized R&D premise of 45,000 square kilometers, 9 production lines within 5 workshops which are powder for injection, oral solution and oral solid ( for cephalosporins and non-cephalosporins ). The company is in line with the EU GMP quality management, produced a series of market leading products with stringent quality control and management system and powerful marketing network. DaliXin (Cefuroxime axetil tablets and capsules) is the best player, leading the Dali brand and Zhijun brand to the top of the marketplace. The company is expanding the business in overseas markets and building strong reputation profile in global marketplace.
The Zhijun Product line has extended to the healthcare and OTC products. In the near future, Zhijun Pharma will take advantage of the SINOPHARM manufacture and sales integration, combine the API supplying to reduce the production cost and expand the scale, thus driving itself to be the core enterprise in the China Pharmaceutical Group Manufacturing lineup.
Volume trading today the highest it's been in 4months. Something coming?
I did it for you buddy! Good night
Way oversold here. Getting me some shares in the morning.
Another PR on the product FDA filings:
Cyplasin Biomedical Prepares A Biosimilar Pegylated Interferon-alpha (C-Pegferon(TM)) for Market Approval in the U.S., E.U. and Major Market Regions EDMONTON, June 28 /CNW/ - Cyplasin Biomedical (CPBM: OTCBB and XYI1:FRA) is a product-oriented, specialty pharmaceutical company focused on developing products for the multi-billion dollar hepatitis C virus (HCV) market. Cyplasin has amassed a portfolio of key products for the prevention and treatment of HCV infection, which affects over 4 million people in the U.S. and several hundred million people worldwide.
One such anti HCV product is known as Interferon-alpha which was approved by the FDA for treatment of HCV infection in 1997. This drug is administered to HCV-infected patients three-times-a-week by injection, for a period up to 1-2 years to achieve a clinical effect. In 2001, a newer, longer-lasting formulation of interferon-alpha called Pegylated interferon-alpha2A and -alpha2B (Roche Pegasys(R) and Schering-Plough Pegintron(R), respectively) were approved for use. The longer-acting version of interferon-alpha only needs to be administered once-per-week for 1-2 years.
Cyplasin recently signed an agreement with Minapharm Pharmaceuticals to distribute and market their version of the long-acting pegylated interferon-alpha product (to be marketed and sold under Cyplasin's brand name C-Pegferon(TM)) within the North American and South American markets as well as Mexico, Latin America, Korea, Russia, China, India and other countries. Cyplasin will be one of the first companies with a biosimilar long-acting interferon-alpha formulation for treatment of hepatitis C patients in North America. Minapharm's pegylated interferon-alpha product is currently sold in the Middle East and Northern Africa region.
The combined market for ribavirin and the long-acting interferon-alpha therapy is estimated to be over $2 Billion annually and Cyplasin now has generic versions of both drugs. Cyplasin will start the process to acquire regulatory marketing approvals to sell the generic drugs in territories outside of North America this July and expects to be on track for other regulatory approvals for the North American market by 2012.
Garth Likes, the CEO of Cyplasin, stated "There are generic drug companies, such as the Israeli company Teva and the Indian companies Dr. Reddy and Wockhardt, that have programs seeking approval of biosimilar or generic short-acting interferon-alpha. Where we can make a difference to our market and revenue stream is that we have partnered with Minapharm who are already selling a commercially viable form of the much improved, long-acting interferon-alpha product. It places us strategically well ahead of a small but elite group of companies in the hepatitis C product area. In combination with our ribavirin product, C-Virin(TM), we anticipate we will be able to start the market application process and submit our dossier to the various regulatory authorities for approval to begin selling C-Pegferon(TM) to governments and healthcare providers who are looking for more reasonably priced HCV drug products".
Mr Likes went on to state "Minapharm will also be our partner to manufacture, test and commercialize our HCV vaccine (C-Vaxin(TM)) in the same territory covered by the C-Virin(TM) distribution agreement."
The Middle East /MENA (Middle East/North Africa) territory includes: the Middle East, Africa and other industrialized regions: Afghanistan, Algeria, Armenia, Azerbaijan, Bahrain, Cyprus, Egypt, Georgia, Indonesia, Kazakhstan, Kyrgyzstan, Iraq, Iran, Israel, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Sudan, Syria, Tajikistan, Tunisia, Turkey, Turkmenistan, United Arab Emirates, Uzbekistan and Yemen. By latest census, the MENA region comprises approximately 6 - 7% of the world's population (ca. 380 million people), a population equivalent to the European Union, or about one quarter larger than the U.S.
Yes. It was final last year. Trying to get the FDA filings and statuses for the 4 products. 1 looks like it's already approved for marketing and sale in the US. Not sure about the other 3
http://www.minapharm.com/index1.html
Press release from MINAPHARM on the partnership last year